[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@Ceazar_Black](/creator/twitter/Ceazar_Black)
"Its been a few weeks since Ive posted. Ive been deep in a complex extended project that demanded full focus. But Ive kept following developments closely and I want to take a moment to respond to this recent post on $ALLR and $MRK"  
[X Link](https://x.com/Ceazar_Black/status/1980614718873092581) [@Ceazar_Black](/creator/x/Ceazar_Black) 2025-10-21T12:38Z XXX followers, 4208 engagements


"$ALLR First off let me say: Allarity is on track. Everything continues to move in the right direction and as we close out Q4 2025 heading into Q1 2026 the setup could not look better. Im personally very excited about where things stand. Theres real momentum behind the science and the story"  
[X Link](https://x.com/Ceazar_Black/status/1980614721309941844) [@Ceazar_Black](/creator/x/Ceazar_Black) 2025-10-21T12:38Z XXX followers, XXX engagements


"$ALLR That said this post highlighting Mercks new KEYNOTE-B96 data caught my attention - because it mirrors exactly what weve seen before with Corcept Therapeutics. The same pattern: chemo-based combination modest incremental benefit enormous toxicity etc etc and then reality sets in"  
[X Link](https://x.com/Ceazar_Black/status/1980614723415449728) [@Ceazar_Black](/creator/x/Ceazar_Black) 2025-10-21T12:38Z XXX followers, XXX engagements


"$ALLR Lets look at what actually happened in KEYNOTE-B96. Merck combined Keytruda (pembrolizumab) with weekly paclitaxel bevacizumab for platinum-resistant recurrent ovarian cancer. The result A hazard ratio of XXXX for progression-free survival statistically positive but clinically modest"  
[X Link](https://x.com/Ceazar_Black/status/1980614725357445454) [@Ceazar_Black](/creator/x/Ceazar_Black) 2025-10-21T12:38Z XXX followers, XXX engagements


"$ALLR Stenoparib doesnt need Keytruda. It doesnt need chemo. And it doesnt need to trade tolerability for temporary survival gains. Its showing something far more important - durable disease control with quality of life preserved"  
[X Link](https://x.com/Ceazar_Black/status/1980614742994501827) [@Ceazar_Black](/creator/x/Ceazar_Black) 2025-10-21T12:38Z XXX followers, XXX engagements


"$ALLR When XX % of patients on the Merck regimen experience adverse events and two-thirds are grade 3-5 thats not progress- thats endurance testing. Allaritys data show that oncology doesnt have to look like that anymore"  
[X Link](https://x.com/Ceazar_Black/status/1980614744802254918) [@Ceazar_Black](/creator/x/Ceazar_Black) 2025-10-21T12:38Z XXX followers, XXX engagements


"$ALLR As investors and observers weve got to separate incremental from transformational. Corcepts chemo combo Incremental. Mercks chemo + ICI + Bev Incremental. Allaritys oral dual PARP/Tankyrase inhibitor with biomarker-guided selection Transformational"  
[X Link](https://x.com/Ceazar_Black/status/1980614747579109468) [@Ceazar_Black](/creator/x/Ceazar_Black) 2025-10-21T12:38Z XXX followers, XXX engagements


"$ALLR So yes Mercks data may make headlines. But the future belongs to therapies that spare patients the toxicity of the past. Thats where Allarity is headed. And thats why Im so excited heading into 2026"  
[X Link](https://x.com/Ceazar_Black/status/1980614749533380665) [@Ceazar_Black](/creator/x/Ceazar_Black) 2025-10-21T12:38Z XXX followers, XXX engagements


"$ALLR Make no mistake. This trading at cash is dumb. Potentially 15-20x within a year on the low side even wo breakthrough designation. With that can easily go 40-50x don't sleep on this"  
[X Link](https://x.com/Ceazar_Black/status/1978834430274752744) [@Ceazar_Black](/creator/x/Ceazar_Black) 2025-10-16T14:44Z XXX followers, 2847 engagements


"$ALLR My take on $MRK ovarian data"  
[X Link](https://x.com/Ceazar_Black/status/1980616313144791108) [@Ceazar_Black](/creator/x/Ceazar_Black) 2025-10-21T12:45Z XXX followers, 1489 engagements